Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting

@article{Bregni2009LongtermFO,
  title={Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting},
  author={Marco Bregni and Massimo Bernardi and Paolo Servida and Alessandra Pescarollo and Roberto Crocchiolo and Elio Treppiedi and P. Poggi – Corradini and Fabio Ciceri and Jacopo Peccatori},
  journal={Bone Marrow Transplantation},
  year={2009},
  volume={44},
  pages={237-242}
}
SCT from an HLA-compatible sibling donor is an adoptive immunotherapy for cytokine-refractory, metastatic clear-cell renal cell cancer (RCC). However, the recent introduction of targeted therapy compounds has reduced the interest in this therapeutic strategy. We have reanalyzed our series with the aim to assess long-term benefit from allografting. Twenty-five RCC patients received a reduced-intensity allograft from an HLA-identical sibling donor. All patients received a thiotepa, fludarabine… CONTINUE READING